Alexis Borisy (Han jingyu/Imaginechina via AP Images)
Overboard: Alexis Borisy will have to limit director posts to stay on at Blueprint
Repeat biotech founder Alexis Borisy will have to give up at least two of his public board seats within a year, since the investor is no longer in compliance with Blueprint Medicines’ corporate policy.
For now, Blueprint is loosening its recently enacted rule that restricts its members to no more than four public board seats at a time so that Borisy can remain on the board. He co-founded the oncology and blood disorder company in 2011.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
